The University of Southampton
University of Southampton Institutional Repository

Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma

Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma
Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma
Immunization of mice with the idiotype (Id) immunoglobulin from the murine B cell lymphoma, BCL1, before inoculating tumor cells can induce tumor dormancy. In this model, the tumor cells grow for a short period of time and then regress. The mice live for months or years with approximately 1 million tumor cells in their spleens. Some mice relapse due to decreases in the anti-Id antibody titers or the development of mutations in the residual tumor cells which render them refractory to negative signaling by the anti-Id antibody. In this study we determined whether we could eliminate the residual dormant cells by using a DNA vaccine against the Id or by immunomodulation of T-cell subsets in vivo. Our results demonstrate that dormancy can be maintained by further immunizations with either the BCL1 Id protein or DNA vaccine encoding its single-chain Fv fragment. We also found that a cytotoxic T-cell response was not induced by either in vivo administration of vaccine alone or by the vaccine plus interleukin-2. In addition the injection of anti-cytotoxic T-lymphocyte-associate antigen did not prolong dormancy. Finally, the in vivo administration of anti-CD25 to deplete regulatory T cells did not prolong dormancy. Dormancy in this model is dependent primarily upon anti-Id antibodies, our results suggest that other strategies to target residual dormant BCL1 cells are warranted. They also suggest that the elimination of dormant tumor may represent a greater challenge than the elimination of primary tumors.
1524-9557
525-534
Pop, Laurentiu M.
1f05dcbb-bb7c-46b5-b3c0-dffe8fbd14ae
Smallshaw, Joan E.
68c782c0-5ffb-4110-ad4e-7c0ba70c34e9
Tucker, Thomas F.
e315d8c0-808c-42e3-83ca-549006e61aa1
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Vitetta, Ellen S.
af8d0814-e2da-4b80-b80a-b96ffde6ef20
Pop, Laurentiu M.
1f05dcbb-bb7c-46b5-b3c0-dffe8fbd14ae
Smallshaw, Joan E.
68c782c0-5ffb-4110-ad4e-7c0ba70c34e9
Tucker, Thomas F.
e315d8c0-808c-42e3-83ca-549006e61aa1
Stevenson, Freda K.
ba803747-c0ac-409f-a9c2-b61fde009f8c
Vitetta, Ellen S.
af8d0814-e2da-4b80-b80a-b96ffde6ef20

Pop, Laurentiu M., Smallshaw, Joan E., Tucker, Thomas F., Stevenson, Freda K. and Vitetta, Ellen S. (2005) Failure of vaccination with idiotypic protein or DNA, (+/-IL-2), the depletion of regulatory T cells, or the blockade of CTLA-4 to prolong dormancy in mice with BCL1 lymphoma. Journal of Immunotherapy, 28 (6), 525-534.

Record type: Article

Abstract

Immunization of mice with the idiotype (Id) immunoglobulin from the murine B cell lymphoma, BCL1, before inoculating tumor cells can induce tumor dormancy. In this model, the tumor cells grow for a short period of time and then regress. The mice live for months or years with approximately 1 million tumor cells in their spleens. Some mice relapse due to decreases in the anti-Id antibody titers or the development of mutations in the residual tumor cells which render them refractory to negative signaling by the anti-Id antibody. In this study we determined whether we could eliminate the residual dormant cells by using a DNA vaccine against the Id or by immunomodulation of T-cell subsets in vivo. Our results demonstrate that dormancy can be maintained by further immunizations with either the BCL1 Id protein or DNA vaccine encoding its single-chain Fv fragment. We also found that a cytotoxic T-cell response was not induced by either in vivo administration of vaccine alone or by the vaccine plus interleukin-2. In addition the injection of anti-cytotoxic T-lymphocyte-associate antigen did not prolong dormancy. Finally, the in vivo administration of anti-CD25 to deplete regulatory T cells did not prolong dormancy. Dormancy in this model is dependent primarily upon anti-Id antibodies, our results suggest that other strategies to target residual dormant BCL1 cells are warranted. They also suggest that the elimination of dormant tumor may represent a greater challenge than the elimination of primary tumors.

This record has no associated files available for download.

More information

Published date: 2005

Identifiers

Local EPrints ID: 26531
URI: http://eprints.soton.ac.uk/id/eprint/26531
ISSN: 1524-9557
PURE UUID: cb716a78-a09e-432b-b377-3b97563dec1f
ORCID for Freda K. Stevenson: ORCID iD orcid.org/0000-0002-0933-5021

Catalogue record

Date deposited: 10 Apr 2006
Last modified: 23 Jul 2022 01:41

Export record

Contributors

Author: Laurentiu M. Pop
Author: Joan E. Smallshaw
Author: Thomas F. Tucker
Author: Ellen S. Vitetta

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×